Compare Fox Corp Class B (FOX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs 10X Genomics Inc — how do they compare? Fox Corp Class B trades at $55.94 (market cap $25.36B), while 10X Genomics Inc trades at $80.95 (market cap $10.07B). The key difference: Fox Corp Class B is far larger — about 2.5× 10X Genomics Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and 10X Genomics Inc for 91 Days on average.
| FOX | TXG | |
|---|---|---|
Market Cap | $25.36B | $10.07B |
Volume | 886,620 | 5,657,286 |
Sector | Media | Health |
52-Week High | $67.76 | $97.74 |
52-Week Low | $44.39 | $11.48 |
Typical Hold Time | 75 Days | 91 Days |
Enterprise Value | $28.72B | $9.59B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.13, up 0.27% today, with a bullish technical signal from moving averages and a consensus analyst price target of $84.75 implying significant upside. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Fundamentals show robust growth, with 2025 revenue reaching $16.30 billion and net income margin improving to 13.88%.
The outlook is positive given valuation multiples below industry averages and consistent earnings outperformance, but risks include a projected net cash flow decline in 2026 and competitive pressures in the media sector. Investor sentiment is mixed, with analyst ratings nearly evenly split between Buy and Hold.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
